Table 1

Demographics and baseline characteristics of study participants

VariablePlacebo
(n=17)
Cenerimod
0.5 mg
(n=12)
1 mg
(n=12)
2 mg
(n=13)
4 mg
(n=13)
Total patients (N=67)
Sex, n (%)
Females16 (94.1)11 (91.7)12 (100)12 (92.3)10 (76.9)61 (91.0)
Males1 (5.9)1 (8.3)1 (7.7)3 (23.1)6 (9.0)
Age (years)
Mean±SD41.0±9.541.4±13.237.0±6.439.2±11.841.7±8.140.1±9.9
Range27–6221–6124–4820–6029–5620–62
Race, n (%)
Caucasian15 (88.2)12 (100)12 (100)13 (100)13 (100)65 (97.0)
African-American2 (11.8)2 (3.0)
Years from first SLE symptom
Mean±SD7.75±5.776.68±6.459.51±7.179.29±7.314.35±2.837.51±6.18
Median7.93.78.26.74.66.0
Range1.1–22.11.6–23.70.6–22.51.4–20.90.8–10.50.6–23.7
Years from first SLE diagnosis
Mean±SD6.25±5.885.59±6.427.31±6.116.29±5.493.01±2.485.70±5.49
Median4.92.46.24.52.93.8
Range0.5–21.41.4–23.70.5–22.31.3–17.00.6–9.20.5–23.7
Number of ACR criteria ongoing at screening, n (%)
0–36 (35.3)5 (41.7)3 (25.0)5 (38.5)1 (7.7)20 (29.9)
4–1111 (64.7)7 (58.3)9 (75.0)8 (61.5)12 (92.3)47 (70.1)
  • FAS (N=67).

  • ACR, American College of Rheumatology; FAS, full analysis set; SD, standard deviation.